Integrated BioTherapeutics Inc. (IBT, www.integratedbiotherapeutics.com), founded by Dr. M. Javad Aman in 2005, is a research and development firm that specializes in protecting against Staphylococcus aureus (S. aureus) bacterial infections as well as Ebola and Marburg filoviruses. Spanning both the public health and bio-defense arenas, IBT is a recognized leader in the field of vaccine development and filovirus research. The company is currently developing a virus-like particle filovirus vaccine product.
Both Aman and IBT co-owner Dr. Kelly Warfield were researchers at the U.S. Army Research Institute for Infectious Diseases.
In 2008, IBT won a $22-million, four-year advanced development cost-reimbursement contract with the National Institute for Allergy and Infectious Diseases to develop a multivalent pan-filovirus vaccine. At the same time, IBT began its services business, called IBT Bioservices, which provides early research and development services to clients working with infectious disease vaccines and therapeutics.
“The business leverages IBT’s core infectious disease expertise and skills in animal model development, assay development, small molecule screening, and vaccine and therapeutics product development,” explained IBT spokesperson Molly Boyle.
By working directly with other scientists, IBT has differentiated itself from most other service firms in the industry, she added. “By working directly with clients in an advisory role, we are involved in design of the early research path including experimental design and, in some cases, we have had our team serve as contract project leaders for clients.”
